Los trastornos del espectro de la esquizofrenia (SSD) son enfermedades mentales que parecen estar provocadas por una combinacion de multiples factores geneticos y ambientales. Entre los factores ambientales desencadenantes, el papel de los eventos traumaticos sufridos en la infancia y el consumo de sustancias resultan de particular interes para...
-
May 16, 2023 (v1)PublicationUploaded on: May 17, 2023
-
October 26, 2023 (v1)Publication
Schizophrenia (SZ) is associated with an increased risk of life-long cognitive impairments, age-related chronic disease, and premature mortality. We investigated evidence for advanced brain ageing in adult SZ patients, and whether this was associated with clinical characteristics in a prospective meta-analytic study conducted by the ENIGMA...
Uploaded on: November 25, 2023 -
November 3, 2022 (v1)Publication
Risk of suicidal behaviour (SB) in schizophrenia spectrum disorders (SSD) is a major concern, particularly in early stages of the illness, when suicide accounts for a high number of premature deaths. Although some risk factors for SB in SSD are well understood, the extent to which personality traits may affect this risk remains unclear, which...
Uploaded on: March 24, 2023 -
May 18, 2023 (v1)Publication
This article describes data related to the research study entitled "Duration of active psychosis during early phases of the illness and functional outcome: The PAFIP 10-year follow-up study." [1]. We present data concerning the clinical and sociodemographic characteristics of a sample of drug-naïve patients with a first episode of non-affective...
Uploaded on: May 20, 2023 -
January 9, 2024 (v1)Publication
While sex differences in schizophrenia have long been reported and discussed, long-term sex differences in outcomes among first episode of psychosis (FEP) patients in terms of the efficacy of Early Intervention Services (EIS) has been an under-explored area. A total of 209 FEP patients (95 females and 114 males) were reassessed after a time...
Uploaded on: January 12, 2024 -
May 12, 2023 (v1)Publication
Background: Few investigations have been carried out on metabolic syndrome in antipsychotic- naïve patients with schizophrenia. Methods: Our primary objective was to compare the prevalence of Metabolic Syndrome (MetS), as defined by the National Cholesterol Education Program, Adult Treatment Panel III in 2001 (NCEP-ATP III), between a...
Uploaded on: May 13, 2023 -
September 27, 2022 (v1)Publication
Background: Patients with a first episode of psychosis (FEP) are at higher risk of gaining weight and presenting metabolic disturbances, partly related to antipsychotic exposure. Previous studies suggest that treatment discontinuation might have a positive impact on weight in schizophrenia. The aim of this study was to evaluate the effect of...
Uploaded on: December 4, 2022 -
May 30, 2023 (v1)Publication
Background People with psychosis are at higher risk of cardiovascular events, partly explained by a higher predisposition to gain weight. This has been observed in studies on individuals with a first-episode psychosis (FEP) at short and long term (mainly up to 1 year) and transversally at longer term in people with chronic schizophrenia....
Uploaded on: May 31, 2023 -
November 29, 2023 (v1)Publication
Toll-like receptors (TLRs) are a pivotal component of the innate immune system that seem to have a role in the pathogenesis of psychosis. The purpose of this work was to compare the expression and functionality of 9 TLRs in three peripheral blood mononuclear cells (PBMCs) (monocytes, B cells, and T cells) between 33 drug-naïve first-episode...
Uploaded on: December 3, 2023 -
May 22, 2023 (v1)Publication
Background Antipsychotic choice for the acute phase of a first episode of psychosis (FEP) is of the utmost importance since it may influence long-term outcome. However, head-to-head comparisons between second-generation antipsychotics remain scarce. The aim of this study was to compare the effectiveness in the short term of aripiprazole and...
Uploaded on: May 24, 2023